RT  - European Journal of Gynaecological Oncology
ID  - 10.31083/j.ejgo.2021.02.2238
T1  - Risk of secondary malignancies in patients with ovarian cancer: a systematic review and meta-analysis
A1  - Keyvan Heydari
A1  - Sahar Rismantab
A1  - Reza Alizadeh-Navaei
A1  - Amir Shamshirian
A1  - Nima Shadmehri
A1  - Parisa Lotfi
A1  - Pouya Houshmand
A1  - Alieh Zamani-Kiasari
A1  - Danial Shamshirian
K1  - Ovarian cancer;
Secondary malignancy; Secondary cancer; SIR; Meta-analysis
YR  - 2021
SP  - 234
AB  - <p>Objective: This study was performed to systematically assess the risk of secondary malignancies in patients
with ovarian cancer. Methods: A systematic search was conducted in PubMed, Web of Science, and Scopus databases up
to September 2019. In this study, the
overall standardized incidence ratio (SIR) was calculated applying fixed/random-effects models. Sixteen cohort studies,  including 122715 ovarian cancer patients with 4458 secondary malignancies were
included. Results: Combined SIRs
showed an increased risk of secondary malignancies prevalence (SIR = 1.81, 95% CI 1.58--2.03). The most common
malignancies were cervical cancer 11.57 (6.94-- 16.21), endometrium 6.31 (4.18--8.44), leukemia 3.33 (2.23--4.43), connective
tissue 2.61 (1.56--3.66), bladder 2.13 (1.77--2.50), renal 1.43 (1.11--1.74), intestine
2.36 (1.11--3.61), colorectal 1.73 (1.44--2.02), pancreatic 1.42 (1.13--1.71), breast
1.34 (1.5--1.18), and thyroid 1.59 (1.13--
2.04) cancers. <i>Conclusion</i>: Somemalignancieswerefoundtobehighly
prevalent in patients with ovarian
cancer compared to the general population, including endometrial cancer, leukemia, connective tissue malignancy, and bladder cancer. Therefore, efforts for early detection, which could lead to improved survival should be taken in these patients.</p>